• Toremifene in Breast Cancer: Evidence Across 20 Years

  2026-08-25

  This review synthesizes two decades of clinical and pharmacologic evidence for toremifene, a selective estrogen receptor modulator used in hormone-sensitive breast cancer. Its central contribution is a balanced positioning of toremifene relative to tamoxifen and aromatase inhibitors, emphasizing comparable clinical utility, distinct metabolism, and patient-specific treatment selection rather than a universal safety advantage.

• Bufalin N1507: Reliable Cell Assay Workflows

  2026-08-25

  This scenario-driven guide shows how Bufalin, SKU N1507, can be integrated into reproducible cell viability, proliferation, and cytotoxicity workflows. It covers solvent control, exposure design, mechanism-aware interpretation, and practical product selection using documented purity, solubility, and storage specifications.

• Tunicamycin: From ER Stress to Translational Strategy

  2026-08-24

  Tunicamycin is more than a laboratory ER stress reagent: as a N-glycosylation inhibitor, it provides a mechanistic lens for connecting protein quality control, macrophage inflammation, and cancer biology. This article outlines how to use it rigorously, interpret its limitations, and translate glycosylation insights into stronger experimental strategies.

• Carbapenemase Gene Spread in Enterobacter cloacae

  2026-08-24

  A 2025 multicenter study mapped carbapenemase-encoding genes, plasmid transfer, mobile genetic elements, and strain relatedness in carbapenem-resistant Enterobacter cloacae from eight Guangdong teaching hospitals. Its findings highlight plasmid-associated blaNDM-1, frequent horizontal transfer, and hospital-spanning strain lineages as important considerations for carbapenem-resistant bacterial infections and surveillance design.

• Hypoxia-Immunometabolism in the Tumor Microenvironment

  2026-08-23

  This 2025 Cancer Letters review integrates tumor hypoxia with immunometabolic competition to explain how oxygen and nutrient scarcity promote immune dysfunction, tumor adaptation, and progression. Its main practical contribution is a framework for studying tumor cells and immune cells as metabolically coupled populations rather than as isolated systems.

• Perospirone: From Receptors to Kv1.5 Assays

  2026-08-22

  Perospirone (SM-9018 free base) combines high-affinity serotonergic and dopaminergic receptor activity with a newly characterized vascular Kv-channel effect. This practical guide shows how to separate receptor pharmacology from ion-channel off-target testing in schizophrenia research and translational assays.

• G-1: Practical GPR30 Assay Guidance

  2026-08-22

  This scenario-based guide explains how G-1 (CAS 881639-98-1), a selective GPR30 agonist, can improve interpretation of viability, proliferation, migration, and cytotoxicity experiments. It connects SKU B5455 specifications with receptor biology, solvent handling, literature benchmarks, and practical vendor-selection criteria.

• Thapsigargin: SERCA Workflows for ER Stress

  2026-08-21

  Thapsigargin provides a rapid calcium-first perturbation for linking SERCA inhibition to endoplasmic reticulum stress, inflammasome signaling, and apoptosis. This practical guide covers assay design, comparative controls, protocol starting points, and troubleshooting for cell-based and disease-model workflows.

• Digestive Metabolism of Withania somnifera Extracts

  2026-08-20

  This 2026 study combines simulated gastrointestinal digestion, LC–MS/MS, targeted analysis, and untargeted molecular networking to examine how Withania somnifera leaf and root extracts change before absorption. Withaferin A and withanoside IV were labile, whereas withanolide A remained comparatively stable, demonstrating why botanical bioavailability requires matrix-aware digestive profiling.

• Cabozantinib: Mapping Adaptive Signaling in RCC

  2026-08-20

  Cabozantinib, also known as XL184, is more than a broad-spectrum kinase inhibitor: it is a practical model for studying how tumors rewire signaling over time. This thought-leadership analysis connects its VEGFR, MET, RET, AXL, and related RTK activity with phosphoproteomic evidence from renal cell carcinoma, translating those findings into experimental design, assay strategy, and a forward-looking framework for translational research.

• L-Phenylephrine and the Sex-Specific α1A Axis

  2026-08-19

  L-Phenylephrine offers translational researchers a selective adrenergic α1A receptor agonist for probing vascular, cardiac, neural, and sex-dependent physiology. By connecting receptor pharmacology with the sex-specific autonomic findings of angiotensin II hypertension research, this article presents a practical framework for assay design, validation, and translational interpretation.

• Quercetin Blocks Ferroptosis in Wilson’s Disease

  2026-08-19

  A 2026 Phytomedicine study identifies ferroptosis as a mechanistic contributor to Wilson’s disease-associated liver injury and shows that Quercetin protects experimental liver tissue by targeting the ACSL4/LPCAT3/ALOX15 lipid-peroxidation axis. The work combines animal and cell models with lipidomics, biophysical binding assays, and ACSL4 overexpression to connect altered phospholipid metabolism with hepatic protection.

• Dextrose (D-Glucose) in Metabolism Research

  2026-08-18

  Dextrose, or D-glucose, is a defined monosaccharide substrate for glucose metabolism research, cell culture media supplementation, and cellular energy production studies. Product specifications for A8406 support controlled preparation, while tumor-immunometabolism literature shows why glucose availability must be treated as an experimental variable rather than a neutral background condition.

• Estradiol Workflow for Estrogen Receptor Studies

  2026-08-18

  Build reproducible 17 beta-estradiol experiments that connect receptor activation with transcription, autophagy, and multi-organ phenotypes. This workflow emphasizes dose control, receptor-aware controls, and translational readouts for cardiovascular, renal, cancer, and endocrine research.

• Bestatin Hydrochloride: From Enzymes to Translation

  2026-08-17

  Bestatin hydrochloride, also known as Ubenimex, is more than a generic aminopeptidase inhibitor. Its ability to perturb aminopeptidase N and B activity creates a practical bridge between neuronal peptide processing, angiogenesis inhibition, and translational cancer research. This article examines the evidence, experimental design implications, and strategic opportunities for using the compound responsibly.

7955 records 1/531 page Next 12345 下5页 Last page